Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Myasthenia Gravis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Carcinosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Endometrioid 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

efgartigimod alfa 2Rituximab 2Hizentra 2zilucoplan 1thymoglobulin 1rozanolixizumab 1rhoA GTP-Binding Protein 1prednylidene 1iscalimab 1inebilizumab 1gamma-Globulins 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1apraclonidine 1Sternotomy 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Immunoglobulins, Intravenous 1HBM9161 1Fluid Therapy 1Etoposide 1Cytarabine 1Carmustine 1CK-2017357 1Bortezomib 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myasthenia Gravis × Fluid Therapy × Clear all
NCT02100969 2021-06-02

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

University of Kansas Medical Center

Phase 2 Completed
23 enrolled 18 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡